LL-37 vs Semaglutide
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of LL-37 and Semaglutide (also searched as Semaglutide vs LL-37) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
LL-37 centers on healing, while Semaglutide leans toward metabolic. On indexed research, LL-37 is ahead (LL-37: 5 studies, Human evidence; Semaglutide: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •LL-37 is strongest for healing; Semaglutide for metabolic.
- •Evidence: LL-37 Human evidence (5 studies) vs Semaglutide Human clinical (5).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Human Cathelicidin | Antimicrobial Peptide
GLP-1 Receptor Agonist | Weight Loss & Diabetes
LL-37 vs Semaglutide: side-by-side
| Metric | LL-37 | Semaglutide |
|---|---|---|
| Class | Immune | Weight Loss |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 5 | 5 |
| Research level | Well Studied | FDA Approved |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 5.0▲ | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 5.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 0.0 |
| Skin & aesthetics | 0.0 | 4.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | LL-37 | Semaglutide |
|---|---|---|
| Mechanism | — | GLP-1 receptor agonist |
| Route | — | Subcutaneous injection (oral form also available) |
| Half-life | — | ~7 days (≈165 h) |
| Time to peak | — | 1–3 days |
| Duration of action | — | Weekly dosing |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →What is Semaglutide?
### Semaglutide Summary Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its role in managing type 2 diabetes and obesity. Its efficacy in promoting weight loss and improving glycemic control has garnered significant attention in recent clinical research.
Full Semaglutide profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Metabolic | Semaglutide | 5.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | Semaglutide | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack LL-37 and Semaglutide?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
LL-37 vs Semaglutide: side effects
No community-reported effects logged yet.
- reduced appetite22
- early satiety17
- nausea9
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
LL-37 has 5 approved studies indexed (Human evidence), and Semaglutide has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is LL-37 or Semaglutide better?
It depends on your goal. LL-37 is strongest for healing; Semaglutide for metabolic. LL-37 has more indexed studies (5). See the goal-by-goal breakdown above.
Is LL-37 or Semaglutide better for weight loss?
Semaglutide shows the stronger metabolic & appetite profile (5.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, LL-37 or Semaglutide?
LL-37 has 5 approved studies indexed (Human evidence); Semaglutide has 5 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack LL-37 and Semaglutide?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of LL-37 vs Semaglutide?
LL-37: no community-reported effects logged yet. Semaglutide: reduced appetite, early satiety, nausea. These are anonymous reports, not incidence rates — see each profile.
Is LL-37 or Semaglutide FDA-approved?
LL-37 is a research-use compound and is not FDA-approved. Semaglutide is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Semaglutide better than LL-37?
For metabolic, Semaglutide has the edge; for healing, LL-37 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.